

Inhalation & Respiratory Drug Delivery | Connected Devices



B



























RESCON SUMMIT

We are excited to announce our upcoming event in New York on September 28-29 2023, focused on innovations in the respiratory sector and connected devices. This event will bring together key industry experts and thought leaders to discuss the latest trends in Sustainable Inhalation devices, Inhaled mRNA Therapy, and other cutting-edge technologies to overcome lung and pulmonary conditions such as COPD, asthma and cystic fibrosis. With over 25 sessions, attendees will also gain insights on on-body device design and development for large volume delivery while engaging in the latest digital applications for wearable devices.

Inhalation & Respiratory Drug Delivery

Our event will also cover a range of practical topics, including Digital health combination products, Analytical tools for inhaled medicines, Market challenges in inhalation and respiratory drug delivery, Regulatory updates in the global respiratory market, Inhaled drugs through FRI and artificial intelligence AI, Artificial Intelligence in Inhalation Medical Devices, Smart Inhalers and Medical Device Design Strategy. The event will be held in a special venue chosen by our team, providing ample opportunities for networking and forging connections with peers in the industry. We are expecting 100 attendees from leading pharmaceutical and biotechnology companies, including Members of board, C-level, Senior Vice Presidents, Vice Presidents, Directors and Heads of departments. Don't miss this unique and unforevent, where you'll gettable have the opportunity to leaarn about the latest innovations in the respiratory sector and connected devices and connect with other industry leaders. We look forward to seeing you there!

Learn The Key Practical Points

• Learn about the challenges and opportunities in inhaled gene therapies.

• Understand strategies to overcome barriers in pulmonary drug delivery.

• Explore solutions for aerosol delivery through breath-enhanced jet nebulization.

• Gain insights into ensuring safety and compliance in inhalation products.

• Discover innovations in localized lung delivery using layer-by-layer assembled systems.

• Explore the complexities and opportunities in connected health for inhalation devices.

• Learn about technical and reliability considerations in emergency-use nasal products.

• Understand the role of 3D models in preclinical studies of new nasal delivery products.

• Explore integrated in vitro/ex vivo assessment methods for respiratory drug development.

• Gain insights into inhalation drug products and packaging quality standards

• Discuss regulatory initiatives and considerations in inhaler technologies.

• Learn about innovative patient-centric high-dose DPIs for respiratory and systemic indications.

• Understand the requirements and innovation landscape for intra-nasal sprays.

• Explore advancements in powder dosing and DPI manufacturing.

• Gain insights into targeted lung delivery in NTM lung disease and IPF.

• Discover new species-agnostic polymeric nanoparticles for inhalable mRNA across multiple animal species.

• Learn about mitigating nitrosamine drug substance-related impurity risks.

• Explore trends and developments in inhaled pulmonary delivery pipelines.

• Understand the role of cascade impactors in the design of dry powder inhalers.

• Learn about the journey from dry powder to liquid connected devices for inhaled insulin.

• Discuss future trends and collaborations in inhalation technology and drug delivery.

WE ARE MICRONIZATION

Jet-, Pin- & Hammer-Milling **Co- & Cryo-Micronization** Micronization Under Containment Post-Milling Conditioning

APIs & High-Potent APIs Steroids **Cytotoxics & Cytostatics** Controlled Substances

INUNIT JETPHARMA • MICROCHEM ЛСН mdalbosco@munit.com www.munit.com

Meet **The Speakers**



Jeffry Weers

Chief Technology Officer at cystetic Medicines, Inc.



Jaap Wieling Chief Executive Officer at PureIMS



Philip Kuehl Senior Scientist at Lovelace Biomedical



Kalpita Mehta **Principal Combination** Product and Medical Device Expert at Hikma Pharmaceuticals Inc.



Gerald Smaldone

Professor of Medicine, Physiology and Biophysics at Stony Brook University Medical Center



Dujuan Lu Manager/Global Leader-E&L at SGS



John Patton Head of Kindeva's Scientific Advisory Board



Rita Lee

Principal Consultant at Suttons Creek, Inc. Head of packaging & commercial devices at Takeda Pharmaceuticals



Katharina Schwarz

Head Aerosol Technology and Aerosol Biophysics at Fraunhofer Institute



Laura Rotolo

Formulation Chemist at Emory University



Thomas Hofmann

Chief Scientific Officer at Mannkind Corporation



Michael Eakins

Principal Consultant at Eakins & Associates





Carolyn Berg

Vice President, **Business** Development at Catalent Pharma Solutions



Marian Asch

Sales Manager Inhalation Technologies at Harro Höfliger



Beth Laube

Professor Emerita at the Johns Hopkins School of Medicine



Vivek Gupta

Associate Professor, and Scientific Founder at St. John University



Sriman Banerjee



David Cipolla VP of Research at Insmed Incorporated



Matt Riccio

Director of Business Development at Aptar **CSP** Technologies



Hugh Smyth

Professor at The University of Texas at Austin



Scientific Agenda

DAY 0 SEP 27.2023

18:00 - 20:00 Pre-Conference Cocktail Reception



DAY 1 SEP 28.2023

Morning Sessions Chairperson: Vivek Gupta	
08:30 – 08:50	Welcome Coffee & RESCON Summit Registration
08:50 – 09:00	RESCON Summit Opening Speech
09:00 – 09:30	Inhaled Gene Therapies: Challenges, Approaches and Opportunities for Inhaled Delivery
	By Philip Kuehl Senior Scientist at Lovelace Biomedical
09:30 – 10:00	Formulation and Chemistry Strategies to Overcome the Pulmonary Drug Delivery Barriers

	By David Cipolla VP of
	Research at Insmed
	Incorporated
10:00 – 10:30	Barriers to the respiratory delivery of biologics
	By Hugh Smyth Professor at The University of Texas

at Austin

10:30 – 11:00 Morning Coffee Break & Sponsor's Presentation



11:00 – 11:30 Advances in Managing Extractables and Leachables for Inhalation Products: Ensuring Safety and Compliance

> By Dujuan Lu Manager/ Global Leader-E&L at SGS

11:30 – 12:00	Layer-by-Layer Assembled Systems for Localized Lung Delivery of Therapeutic and Diagnostic Agents Pharmaceuticals
	By Vivek Gupta Associate Professor, and Scientific Founder at St. John's University
12:00 – 12:30	Connected Health Opportunities and Complexities of for Inhalation Devices to Consider Prior to Starting Development
	By <mark>Rita Lee</mark> Principal Consultant at Suttons Creek, Inc.
12:30 – 13:00	"Emergency-use" nasals: Technical and reliability considerations
	By Kalpita Mehta Principal Combination Product and Medical Device Expert at Hikma Pharmaceuticals Inc.

13:00 – 14:00 RESCON Business Lunch



Afternoon Sessions Chairperson: Michael Eakins

14:00 – 14:30 The Role of 3D Models of Human Intranasal Airways in Preclinical Studies of New Nasal Delivery Products

	By Beth Laube Professor Emerita at the Johns Hop- kins School of Medicine
14:30 – 15:00	Integrated in vitro/ex vivo assessment of efficacy and respiratory toxicity for accelerated respiratory drug development
	By Katharina Schwarz Head Aerosol Technology and Aerosol Biophysics at Fraunhofer Instituteat Stony Brook University Medical Center
15:00 – 15:30	Solving Problems in Aerosol Delivery: Breath Enhanced Jet Nebulization
	By Gerald Smaldone Pro- fessor of Medicine, Phys- iology and Biophysics at Stony Brook University Medical Center
15:30 – 16:00	Inhalation Drug Products and Packaging Quality: Exploring USP General Chapters and Future Development
	By Michael Eakins Princi- pal Consultant at Eakins & Associates
16:00 - 16:30	Afternoon Break

Panel Discussion: 16:30 – 17:30 DAY 2 Future Trends and Collaborations in Inhalation Technology and Drug Delivery Panelists: – David Cipolla, Insmed Incorporated – Dujuan Lu, SGS - Rita Lee, Suttons Creek, Inc. – John Patton, Kindeva's Scientific Advisory Board – Jeffry Weers, Cystetic Medicines, Inc. Moderated by: Carolyn Berg, Vice President, Business Development at Catalent Pharma Solutions Closing Remarks & End 17:30 of the RESCON Summit 1st day 19:30 – 22:00 RESCON Gala Dinner



SEP 29.2023

Morning Sessions Chairperson:

Thomas Hofmann

09:00 – 09:30 Registration & Morning Coffee



09:30 - 10:00 Inhalation delivery for respiratory and systemic indications using Cyclops™, an innovative patient-centric high-dose DPI By Jaap Wieling Chief

Executive Officer at PureIMS

10:00 – 10:30 Requirements for Intra-nasal Sprays and innovation landscape

> By Sriman Banerjee Head of packaging & commercial devices at Takeda Pharmaceuticals

10:30 – 11:00 Morning Coffee Break



11:00 – 11:30 Powder dosing and DPI manufacturing

By Marian Asch Sales Manager Inhalation Technologies at Harro Höfliger

11:30 – 12:00	Learnings and advances with targeted lung delivery in NTM (nontuberculous mycobacteria) lung disease and IPF (idiopathic pulmo- nary fibrosis)
	By Thomas Hofmann Chief Scientific Officer at Mann- kind Corporation
12:00 – 12:30	New species agnostic polymeric nanoparticles for inhalable mRNA across six animal species
	By Laura Rotolo Formulation Chemist at Emory University
12:30 – 13:00	Mitigating Nitrosamine Drug Substance Related Impurity Risks with Novel Active Material Science Innovations By Matt Riccio Director of Business Development at Aptar CSP Technologies

13:00 – 14:00 RESCON Business Lunch



Afternoon Sessions Chairperson: Carolyn Berg

14:00 – 14:30	Pipeline Overview and Trends in Inhaled Pulmo- nary Delivery
	By Carolyn Berg Vice Pres- ident, Business Develop- ment at Catalent Pharma Solutions
14:30 – 15:00	The role of cascade impactors in the design of dry powder inhalers
	By Jeffry Weers Chief Technology Officer at cystetic Medicines, Inc.
15:00 – 15:30	Inhaled Insulin: from dry powder to liquid connected device
	By John Patton Head of Kindeva's Scientific Advisory Board
15:30	End of RESCON Summit 2023

BIOGRAPHIES



Kalpita Mehta Principal Combination Product and Medical Device Expert at **Hikma Pharmaceuticals Inc**

Kalpita is currently employed at Hik Pharmaceuticals, specializing in con nation products. Her main area of exp tise revolves around developing successfully launching nasal sprays, in lation devices, and similar offerings. V over 14 years of experience in Qua Assurance and Regulatory Affairs with the pharmaceutical and medical dev industries, Kalpita strongly focuses



Katharina Schwarz Head Aerosol Technology and Aerosol Biophysics at Fraunhofer Institute

Dr. Katharina Schwarz (f) leads the depart- Her institutional role involves interfacment "Aerosol Technology and Aerosol ing with the pre-clinical and clinical air-Biophysics" at the Fraunhofer Institute for way research as well as toxicology/risk Toxicology and Experimental Medicine assessment from Fraunhofer ITEM and (ITEM) in Hannover, Germany since 2015. the corresponding sponsors from chem-She is an expert at the interface between ical/pharmaceutical industry or governaerosol/inhalation research, respiratory mental institutions to cover the aerosol/ pharmacokinetics, toxicology/physiology inhalation and dosimetry-related aspects and inhalation exposure science with a in drug development programs, toxispecial focus on lung particle dosimetry cological or inhalation exposure studand biophysical particle-lung interactions. ies including GLP/GCP-compliance.



Laura Rotolo Formulation Chemist at Emory University

Laura is the Lead Formulations chemist S.p.A (Colleretto Giacosa, Turin - IT). at the Department of Chemistry at Emory Laura learned biological and biomedical University under the supervision of Dr. engineering skills during her first post-Dennis Liotta. Laura received her Mas- doc at the Georgia Institute of Techter Degree in Pharmacy from the Univer- nology where she became the lead sity of Turin (Italy) in collaboration with formulation chemist of many projects, DSM Nutritional Product (Basel, Switzer- including 30M\$ DARPA PREPARE funded land) and her PhD in Organic Chemistry ThIRM grant to deliver mRNA to lungs. from University of Turin (Italy) in collab- Her efforts let her lab secured funds oration with Georgia State University also from Bill&Melinda Gates founda-(Atlanta, GA – US) and Bracco Imaging tion for the development of flu vaccines.



Jeffry Weers Chief Technology Officer at cystetic Medicines, Inc.

Jeffry Weers is currently the Chief Tech- from the University of California, Davis. nology Officer at cystetic Medicines, Inc. Jeff has spent the last 25 years of his career cystetic Medicines is focused on devel- focused on the design of formulations opment of a novel genotype independ- and devices for respiratory drug delivery. ent ion channel mimetic that restores In this regard he has worked for numerous anion transport in people with cystic companies including Alliance Pharmaceufibrosis caused by Class 1 and other rare tical Corp., Inhale Therapeutic Systems mutations for which there are currently (now Nektar Therapeutics), Transave, no targeted therapies. He is a physi- Inc. (now Insmed), Novartis Pharmaceucal chemist with a Ph.D. in Chemistry tical Corp., and Respira Therapeutics.



Jaap Wieling Chief Executive Officer at PureIMS

Jaap Wieling brings 30 years of experi- maceutical companies and (biopharmaadvisory committee of various (bio)phar-

ence as an executive and entrepreneur in ceutical) service industries. For many years (bio)pharmaceutical research and devel- he has been invited university lecturer on opment (TNO, DSM, PRA/ICON, Xendo, pharmaceutical product development. He QPS and BiosanaPharma). He is a sea- holds a BSc degree in chemistry, an MSc soned expert in building effective and effi- degree in pharmacology and a PhD degree cient product and platform development in Mathematics and Natural Sciences from businesses and serves on the board and Groningen University, The Netherlands.



Philip Kuehl Senior Scientist at Lovelace Biomedical

Philip Kuehl is a Senior Scientist and Sen- Pharmacy. Dr. Kuehl is a part of the scienior Director of Scientific Core Laborato- tific team at Lovelace that is responsible ries at Lovelace Biomedical in Albuquer- for ~ 10 IND packages per year with focus que, NM. He holds a bachelor's degree in respiratory drug delivery, gene therin biochemistry from Hamline University apy and infectious disease. He has supin St. Paul, MN and a PhD in Pharmaceu- ported two approved inhalation products tical Sciences from The University of Ari- and one DMF. Dr. Kuehl's research interzona, College of Pharmacy in Tucson Ari- ests are in the area of inhalation formulazona. Dr. Kuehl is an Adjunct Professor at tion and its effects on deposition, pharthe University of New Mexico College of macokinetics and pharmacodynamics.

kma	device development, technology transfer,
nbi-	product launches, and quality auditing.
oer-	Throughout her career, Kalpita has played a
and	leading role in supporting the introduction
nha-	of high-risk, complex, and emergency-use
Vith	medical devices. She has made notable
ality	contributions to global markets by success-
thin	fully launching critical respiratory in-vitro
vice	diagnostics (IVD) kits such as SARs-COV-2
on	IVD kits during crucial pandemic years.



Thomas Hofmann Chief Scientific Officer at Mannkind Corporation

Scientific Officer since December 2020 national leader in the study and treatment when MannKind acquired Qrumpharma of pulmonary diseases such as Cystic - a pharmaceutical company with focus Fibrosis, Asthma and COPD. At MannKind, on mycobacterial pulmonary disease that Thomas is focused on leveraging its cut-Thomas founded. He has spent more than ting-edge technology to bring new thera-25 years as a clinical developer of inhaled pies to patients with orphan lung diseases.

Thomas Hofmann is the MannKind as Chief therapies for lung diseases and is an inter-



Michael Eakins Principal Consultant at Eakins & Associates

sultant at Eakins & Associates having bution Expert Committee since 2005 with held senior positions at Bracco S.p.A. 15 years as Vice-Chair including for the and Bristol Myers Squibb. Eakins & Asso- 2020 – 2025 cycle. He has contributed to ciates is a consulting company specializ- over 65 publications and to 6 US patents ing in pharmaceutical primary packaging, and holds a Bachelor's Degree in Physiolespecially glass defects, extractables and ogy and Zoology and a Ph.D. in Physiolleachables from packaging components ogy both from the University of London. and single use systems. He has been a

Michael is President and Principal Con- member of the USP Packaging and Distri-



Gerald Smaldone Professor of Medicine, Physiology and Biophysics at Stony **Brook University Medical Center**

Degree in Chemical Engineering at New Pulmonary Medicine and Environmental York University School of Engineering in Physiology at The Johns Hopkins Univer-1969. In 1975, he completed a combined sity. In 1996 he became Division Head. He M.D., Ph.D. Program at New York Univer- is actively involved in multiple projects utisity School of Medicine. His thesis was lizing aerosols directed towards the study in pulmonary mechanics. Dr. Smaldone of inflammatory airway disease, airway received his clinical training as an intern geometry and drug delivery. In addition and resident in the medicine program at to his research activities, Dr. Smaldone The University of Rochester, New York, actively practices at University Hospital. Strong Memorial Hospital. Between 1977

Dr. Smaldone received a Bachelors and 1980 he completed fellowships in



Dujuan Lu Manager/Global Leader-E&L at SGS

Dr. Dujuan Lu serves as the manager for more than 700 E&L projects on a broad the extractables and leachables (E&L) range of packaging systems, including team at the SGS Health Science Fair- process materials, pharmaceutical finfield New Jersey facility as well as the ished packaging, and medical devices. global leader amongst the global E&L As a subject matter expert in the E&L centers of excellence. Before joining field, she is frequently presenting at var-SGS, she worked at Fresenius Kabi as a ious conferences as invited speakers and research scientist, leading E&L projects technical session chairs. She was named to support transfusion and infusion med- one of the top 60 most influential people ical device and parenteral products. She working in the pharmaceutical industry has extensive CRO and pharmaceutical/ in the Medicine Maker's 2020 power list. medical device industry experience with

Beth Laube Professor Emerita at the Johns Hopkins School of Medicine

Beth L. Laube received her Ph.D. from the assessments. This approach has been very Johns Hopkins Bloomberg School of Pubuseful in the development of aerosol therlic Health and is currently Professor Emerapies for asthma, cystic fibrosis and diaita at the Johns Hopkins School of Medibetes and for answering basic physiologic cine. Dr. Laube's research is translational questions about mucociliary clearance. in nature and is centered on in vivo and She has been a member of the Editorial in vitro quantification of the deposition Board of the Journal of Aerosol Medicine and removal of particles in healthy and (now the Journal of Aerosol Medicine and diseased lungs and noses, using radiola- Pulmonary Drug Delivery) since 1998. beled aerosols and scintigraphic imaging



Vivek Gupta Associate Professor, and Scientific Founder at St. John's University

Dr Vivek Gupta is an associate professor maceutical scalability, and nano-repurof industrial pharmacy at College of Pharposing. Diseases of interest include lung macy & Health Sciences. Dr Gupta's is an cancer, pulmonary fibrosis, pulmonary hypertension, and mesothelioma. Dr. experienced pharmaceutical researcher with interests in developing novel thera-Gupta's research group has published >90 pies for respiratory disorders. His expertise high-impact publications in peer reviewed lies in the fields of novel drug discovery journals. Multiple technologies and therand repurposing, and non-invasive delivapies developed by Dr. Gupta's group ery of small and macromolecules via oral have been patented and are at various and inhalation routes. He also has signifistages of preclinical/clinical development. cant research interest in the fields of phar-



John Patton Head of Kindeva's Scientific Advisory Board

scientist with extensive experience in the Medical Innovation of the year in 2006 for biotech industry and the development of Exubera, the first FDA-approved inhaled new inhaled medications. Within the inha- Insulin; Dance Biopharm (now Aerami lation field, after leading the drug deliv- Therapeutics) in 2009; InCarda Theraery team at Genentech (1985-1990) where peutics in 2009; and iPharma Limited in he helped pioneer inhaled biologics, he 2016 (acquired by Kindeva in 2022). John founded/co-founded 4 inhalation compa- has more than 110 publications and is nies: Inhale/Nektar Therapeutics in 1990, (co)inventor of more than 50 patents.

John is an entrepreneur and drug delivery the recipient of the Wall Street Journal's



Rita Lee Principal Consultant at Suttons Creek, Inc.

strategy experience in regulated medical ing in marketing approvals/clearances. products (combination products, medical Rita's combination products experience devices, and drugs) in startups and larger has centered on drug delivery. She has companies. As global regulatory device guided medical device and combination lead for devices and combination prod- product regulatory strategy for numeructs over 5 years, she interacted with reg- ous products, including infusion pumps ulatory agencies, synergized/collaborated (pre-filled and user-filled), bioelectronwith product teams, and championed/ ics, mobile apps (software as a medical proposed solutions-oriented, risk-miti- device, SaMD), in-vitro diagnostics (IVD), gating regulatory strategy to market and and inhalation devices (nebulizers, DPI).

Rita has 15+ years of regulatory affairs post-market product modifications result-



Sriman Banerjee Head of packaging & commercial devices at Takeda **Pharmaceuticals**

Sriman is the head of packaging & com- agement. He has several global awards mercial devices at Takeda Pharmaceuti- to his credit and presented at several cals. His prior work experience includes conferences on devices and packagworking at GlaxoSmithKline, J&J, and ing. Some of the noted products, he a couple of other companies. He is a has worked on is Flonase, Sensimist, Mechanical Engineer with a master's in Otrivin, Instanyl in the intra-nasal platform Packaging, Plastics, and Financial man-



David Cipolla VP of Research at Insmed Incorporated

David is the VP of Research at Insmed Incor- digm, David worked at Genentech, Inc. porated, where he is part of a team devel- developing and characterizing the delivery oping novel, targeted therapies to help of protein aerosols to the airways, culmiserve the critical unmet needs of patients nating with the approval of Pulmozyme® battling serious rare diseases. Prior to rhDNase for the management of cystic joining Insmed in 2018, David worked at fibrosis in 1993. David holds a chemical Aradigm covering all phases of product engineering degree from MIT (SB) and development and led the development UC Davis (MS) and a pharmacy degree of preclinical research, CMC activities and from the University of Sydney (PhD). intellectual property. Prior to joining Ara-



Carolyn Berg Vice President, Business Development at Catalent Pharma Solutions

Carolyn Berg has over 25 years of expe- various leadership roles within Cipla, Teva rience in pharmaceutical sales, marketing Respiratory and Merck, and owned her and business development. She is currently own consulting practice for pharmaceuti-Vice President, Business Development for cal and healthcare clients. Carolyn holds a Catalent's inhaled drug delivery solutions Bachelor of Journalism in Public Relations where she is responsible for growing the and a Bachelor of Arts in French from the Inhalation business in North America and University of Texas at Austin, and an MBA Europe. Prior to Catalent, Carolyn has held from the University of South Carolina.



Marian Asch Sales Manager Inhalation Technologies at Harro Höfliger

He started his career as Project Mana in Harro Hoefligers Business Unit Ir lation in 2017. In this role he mana-DPI projects of multinational pharma ents worldwide. Since summer 20

ager	Marian Asch works as a Sales Manager
nha-	for Inhalation Technologies focusing
ged	on business development and sales for
cli-	dry powder inhaler pharma industry.
021,	



Matt Riccio Director of Business Development at Aptar CSP Technologies

Matt brings over 20 years of experience ton Dickinson, supporting the Pharmaspanning engineering, sales, and busi- ceutical Systems division and their injectness development roles in the pharma- able drug delivery devices. In this role, ceutical and medical device industries. he worked closely with pharmaceutical He holds both a BS in Mechanical Engi- and biotech customers to understand neering and an MS in Engineering Man- their drug product and delivery needs, agement from Northeastern University. and provide customized device solutions. He spent 14 years of his career with Bec-



Matt Riccio Director of Business Development at Aptar CSP Technologies

nial Professor, College of Pharmacy, The from the University of Otago, New Zea-University of Texas at Austin. Dr Smyth land. He has been faculty at The Univeroversees and multidisciplinary laboratory sity of North Carolina at Chapel Hill, and funded through NIH, FDA, and indus- The University of New Mexico. He was the try that focuses on engineering new American Association of Pharmaceutical drug delivery systems with an emphasis Scientists (AAPS) New Investigator award on drug delivery to the airways. He has winner for Pharmaceutics and Pharmaceuover 300 published works which have tical Technologies in 2007. He also received been cited over 6500 times. Dr Smyth the PhRMA Foundation New Investiis editor of 3 books, and an inventor on gator Award in pharmaceutics in 2007. numerous patents or patent applications.

Hugh D. C. Smyth is the Alcon Centen- He has a Pharmacy and a Ph.D. degree



ORALLY INHALED & NASAL DRUG PRODUCT DEVELOPMENT AND TESTING Supporting global OINDP development for over 30 years

Formulation development

- Specialist support for biologics & DNA medicines Clinical manufacturing
- In-vitro bioequivalence studies
- QC & GMP batch release testing



• CMC package support • ICH stability studies • GMP IV-IVC tools

MILLENNIUM HILTON NEW YORK ONE UN PLAZA One UN Plaza New York 10017 USA

Nestled within the iconic United Nations headquarters in Manhattan, the Millennium Hilton New York One UN Plaza is a beacon of luxury and sophistication. This distinguished hotel offers an unmatched blend of style, comfort, and convenience, making it an ideal choice for travelers and event organizers alike. As you step into the Millennium Hilton, you're immediately embraced by an aura of timeless elegance. The lobby's modern design, featuring sleek lines and contemporary art, seamlessly marries with the hotel's rich history and prestigious location. One of the hotel's most captivating features is its unparalleled views. From many of the rooms and event spaces, guests are treated to breathtaking vistas of the East River, the iconic Chrysler Building, and the awe-inspiring city skyline. These views create an unforgettable backdrop for any stay or event, making every moment truly extraordinary.

Sky-high views in Midtown Manhattan

Hilton

TRACKS

ALLER DE BRA

100000

HILLI











